Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

iTeos Therapeutics
139 Main Street
Cambridge, MA 02142
https://www.iteostherapeutics.com/

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company's lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium.

Key Contact
Name
Michel Detheux
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
04/01/20 $125,000,000 Series B-2 6 Dimensions Capital
Boxer Capital
Curative Ventures
Fund+
HBM Partners
Invus
Janus Henderson Investors
MPM Capital
RA Capital Management
RTW Investments
SRIW
VIVES Louvain Technology Fund
undisclosed